# Idiopathic Interstitial Pneumonia

Group of diffuse parenchymal lung diseases of unclear aetiology that are characterised by:

* Expansion of the pulmonary interstitial compartment
* Inflammatory infiltrate


This classification encompasses a a number of subsidiary interstitial diseases including:

:::column-margin
Acute interstitial pneumonia is also known as Hamman-Rich syndrome.
:::

* **Acute interstitial pneumonia**\
Variant characterised by:
	* Acute onset\
	7-14 days.
	* Rapidly progressive course\
	Generally require intubation within a few days.
	* Diffuse lung injury
* **Organising pneumonia**\
Inflammatory lung disease characterised by granulation in small airways and alveoli. Subdivided into:
	* **Cryptogenic organising pneumonia**\
	No obvious cause.
	* **Secondary organising pneumonia**\
	Following previous alveolar injury, including:
		* Post-infectious\
		See below.
		* Drugs
		* Connective tissue disorders
			* Rheumatoid arthritis
			* Systemic sclerosis
			* Lupus
			* Inflammatory bowel disease
			* Vasculitis
				* Granulomatosis with polyangitis
				* Eosinophilic granulomatosis with polyangitis
		* Transplantation
		* Malignancy
			* Haematological
		* Radiotherapy
			* Thoracic malignancy\
			Generally 3-6 months.
		* Chemotherapy
		* Allogenic BMT
		* Industrial chemical exposure
* **Lymphoid interstitial pneumonia**

:::column-margin
Cryptogenic organising pneumonia was formerly known as bronchiolitis obliterans organising pneumonia (BOOP).
:::

## Epidemiology and Risk Factors

AIP:

* Associated with:
	* Rheumatoid arthritis
	* SLE
	* Dermatomyositis
	* Sj√∂gren's syndrome

COP:

* ~1-5/100,000


## Pathophysiology

Poorly understood, features include:

* Inflammation
* Intra-alveolar fibroproliferation
	* May be reversible
* Fibrinous remodelling


### Aetiology

: Precipitants of Secondary Organising Pneumonia

+-------------------------------+----------------------------+
| Infection                     | Drug                       |
+===============================+============================+
| **Bacteria**:                 | **Common**:                |
|                               |                            |
| * Gram negative cocci:        | * Amiodarone               |
| 	* *Chlamydia pneumoniae*    | * Clopidogrel              |
| * Gram negative bacilli:      | * Dabigatran               |
|    * *Burkholderia cepacia*   | * Hydralazine              |
|    * *Coxiella burnetii*      | * Risperidone              |
|    * *Legionella pneumophila* | * Sertraline               |
|    * *Pseudomonas aeruginosa* | * Sirolimus                |
|    * Serratia marcescens      | * Statins                  |
| *  Gram positive cocci:       | * Methotrexate             |
|    * *S. aureus*              |                            |
|    * *S. pneumoniae*          |                            |
| * Gram-positive bacilli:      |                            |
|    * *Nocardia asteroides*    |                            |
| * Other                       |                            |
| 	 * *Mycoplasma pneumoniae*  |                            |
+-------------------------------+----------------------------+
| **Viruses**:                  | **Immune** and **cancer**: |
|                               |                            |
| * DNA Viruses:                | * Chemotherapies           |
|    * Adenovirus               |     * Bleomycine           |
|    * CMV                      |     * Cyclophosphamide     |
|    * HHV-7                    |     * FOLFIRI              |
|    * HSV                      |     * FOLFOX               |
| * RNA Viruses:                |     * Hydroxyurea          |
|    * COVID-19                 |     * Leflunomide          |
|    * HIV                      |     * Oxiplatin            |
|    * Influenza Virus          | * Checkpoint inhibitors    |
|    * Parainfluenza Virus      | * Monoclonal antibodies    |
|    * RSV                      |                            |
+-------------------------------+----------------------------+
| **Parasites**:                | **Recreational**:          |
|                               |                            |
| * Malaria                     | * Synthetic marijuana      |
| 	* *P. vivax*                | * Vaping                   |
| * *Dirofilaria immitis*       | * Freebased cocaine        |
+-------------------------------+----------------------------+
| **Fungi**:                    | **Chemical**:              |
|                               |                            |
| * *Aspergillus*               | * Textile die              |
| * *Cryptococcus neoformans*   | * Mustard gas              |
| * *Pneumocystis jirovecii*    |                            |
+-------------------------------+----------------------------+

:::column-margin
Atypical infections are more likely to be the primary precipitant.
:::


## Clinical Features

Typically subacute presentation with:

* Dry cough
* Progressive dyspnoea
* Constitutional symptoms
	* Fever
	* Malaise
	* Weight loss

: Features by Cause

+-------+----------------+---------------+
| Cause | Onset          | Cough         |
+=======+================+===============+
| AIP   | * Days-weeks   |               |
|       |                |               |
+-------+----------------+---------------+
| COP   | * Weeks-months | * Unrelenting |
|       |                | * Dry         |
+-------+----------------+---------------+

## Assessment

### History




### Exam

* Bilateral diffuse crepitations

### Investigations

**Bedside**:

* Bronchoscopy
	* BAL\
	To evaluate for eosinophilic pneumonia and alveolar haemorrhage.

**Laboratory**:

* Blood
	* FBE\
	Mild leukocytosis is common.
	* BNP\
	Exclude CCF.
	* Cultures
	* Rheumatological screen
	* Connective tissue disease screen
* Sputum
	* Culture
		* Fungal
		* Atypical organisms
	* Viral PCR
		* Influenza
* Urine
	* Legionella PCR

:::column-margin
{{< include /includes/rheumatoid_screen.qmd >}}
:::

**Imaging**:

:::column-margin
![Organising Pneumonias](/resources/cop.jpeg)
:::

* CXR
	* Consolidative opacities with normal lung volumes\
	Figure A.
* High-resolution CT
	* Multifocal consolidation
	* Peripheral nodulation\
	Figure C.
	* Migratory opacities are classical for organising pneumonia\
	Figure D and E are the same patient at different time points.
	* Atoll sign\
	Rim of consolidation with central ground-glass opacities, which is rare but highly specific.

**Other**:

* Bronchoscopy
	* BAL\
	Evaluate for:
		* Diffuse alveolar haemorrhage
		* Eosinophilia
		* Malignant infiltrates

### Diagnostic Approach and DDx

Key differentials include:

* CAP\
Absence of antibiotic response suggests organising pneumonia.
* Hypersensitivity pneumonitis
* Eosinophilic pneumonia
* Diffuse Alveolar haemorrhage
* Vasculitis
* Pulmonary lymphoma
* Invasive mucinous adenocarcinoma
* Pulmonary sarcoidosis

## Management

:::priority
* **Broad-spectrum antimicrobials**
* Immunosuppression with **corticosteroids**
:::


**Resuscitation**:

**Specific therapy**:

* Pharmacological
	* Antibiotics\
	Commenced empirically until infectious causes are excluded.
	* Corticosteroids\
	1mg/kg prednisolone daily up to 60mg per day, for 2-4 weeks followed by a 3-5 month taper.
* Procedural
	* Lung transplantation
* Physical

**Supportive care**:

**Disposition**:

**Preventative**:


### Marginal and Ineffective Therapies

## Anaesthetic Considerations

## Complications

* Death
	* AIP\
	~50% by 6 months.
* B
	* Chronic interstitial lung disease
	* Relapse
		* Particularly with organising pneumonia


## Prognosis

## Key Studies


---

## References

1. King TE, Lee JS. [Cryptogenic Organizing Pneumonia](https://www.nejm.org/doi/full/10.1056/NEJMra2116777). New England Journal of Medicine. 2022;386(11):1058-1069. doi:10.1056/NEJMra2116777
1. Mrad A, Huda N. [Acute Interstitial Pneumonia](http://www.ncbi.nlm.nih.gov/books/NBK554429/). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Sep 30].

